Legal & General Group
ALGS icon

Legal & General Group’s Aligos Therapeutics ALGS Stock Holding History

Legal & General Group’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-313
Closed -$16K – 3519
2022
Q1 		$16K Hold
313
– – ﹤0.01% 3285
2021
Q4 		$93K Hold
313
– – ﹤0.01% 2925
2021
Q3 		$121K Buy
313
+207
+195% +$81.9K ﹤0.01% 2803
2021
Q2 		$53K Buy
106
+64
+152% +$40.8K ﹤0.01% 2928
2021
Q1 		$24K Hold
42
– – ﹤0.01% 3050
2020
Q4 		$29K Buy
+42
New +$20.5K ﹤0.01% 2958

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Legal & General Group's ALGS Position: Q2 2022 in Review

Legal & General Group sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 313 shares — an estimated $16K sold.

Legal & General Group first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $121K in Q3 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Legal & General Group reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 313 Aligos Therapeutics shares in Q2 2022, an estimated $16K.
  • Legal & General Group first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
  • Legal & General Group's Aligos Therapeutics position peaked at $121K in Q3 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.